Targeting ATXN2 may also treat ALS: intermediate CAG repeat expansions increase ALS risk, and reduction of Atxn2 expression in transactive response DNA-binding protein 43 kDa (TDP-43) transgenic mice increased life span and normalized TDP-43 aggregation (4, 5). This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.